3.3 Social Risk Factors, Access, and Hormone Use

3.3 Social Risk Factors, Access, and Hormone Use

The September 2025 content specifications added more detail on social risk factors. ARRT’s outline groups items you can document in a history: lifestyle (tobacco, body weight, excessive alcohol), access to care / health disparity, and hormone use (menopausal hormone therapy, birth control, and gender-transition hormones). The exam is not asking you to lecture patients. It is asking you to know how these items change risk discussion, screening reliability, and who is more likely to present late.

Lifestyle exposures — document, do not moralize

Alcohol has the clearest lifestyle link to breast cancer among the common social factors. Risk rises with amount; ACS prevention science treats alcohol as a modifiable contributor to a substantial share of breast cancers. You do not need an exact drink-count cutoff for the registry exam. You do need to record heavy or regular use when the history form asks, because it belongs in risk counseling the clinician provides and because it may travel with other access barriers (missed visits, comorbid disease).

Body weight matters in a menopausal-status-specific way. After menopause, adipose tissue is a major source of circulating estrogen; excess body weight is associated with higher postmenopausal breast cancer risk. ACS has also noted that the premenopausal relationship is not the same (excess weight is not a simple “always higher risk” story before menopause). For mammography practice, body habitus also changes technique: more tissue to compress, more likelihood of skin folds, possible need for additional views, and a higher chance that the patient has delayed care because prior compression was painful. That is an imaging implication, not a character judgment. Use the large cassette/detector coverage you need, coach compression in steps, and never treat obesity as a reason to skip a complete exam.

Tobacco is on the ARRT social-risk list even though its breast-cancer association is weaker and more subtype-specific than alcohol’s. Smoking remains a major cause of other cancers, including lung cancer — which the inherent-history list also flags — and it can impair wound healing if biopsy is needed. Record tobacco use. Do not claim on the exam that smoking is the leading cause of breast cancer; it is not. Do not omit it because “breast isn’t a smoking cancer” in popular myth.

None of these lifestyle items lets you refuse screening or announce a diagnosis. They belong on the intake so the care team can counsel and so you can anticipate positioning and follow-up barriers.

Access to care and health disparity

Disparity is an exam topic because it changes whether screening happens on time, stage at diagnosis, and whether the patient can complete a callback. It is not a separate disease biology lecture, although biology (for example a higher rate of triple-negative tumors in Black women) and access travel together.

ACS Cancer Statistics 2026 again reports that non-Hispanic Black women have the highest breast cancer mortality of any U.S. racial or ethnic group. In that report, death rates were on the order of 40% higher than in non-Hispanic White women (about 26.5 versus 19.3 per 100,000 in the figures widely cited from the 2026 ACS paper) even though incidence was slightly lower. ACS attributes much of the gap to differences in access to high-quality prevention, early detection, and treatment, along with risk-factor patterns and underrepresentation in trials. American Indian and Alaska Native women also face mortality that is not explained by incidence alone. White, Asian, and Pacific Islander women are more often diagnosed at a localized stage than Black, Hispanic, American Indian, and Alaska Native women in ACS summaries.

For the mammographer, the operational translation is concrete:

• Missed or delayed screening shifts detection toward later stage. If a patient is three years late, do not scold; complete today’s exam and make the callback process easy to understand.
• Callbacks fail when transportation, childcare, unpaid leave, or copays make a second visit impossible. Explain that additional imaging is usually not a cancer diagnosis, give the time estimate, and involve scheduling or navigation if your site has it.
• Language access is part of results communication. A family member who “speaks English” is not a substitute for a qualified interpreter when you explain a suspicious-result process or a density letter. MQSA already requires the lay summary in terms the patient can understand; an English-only letter to a patient who does not read English fails that purpose even if the stamp date is legal.
• Insurance and undocumented status affect whether the patient has a named provider. Remember the MQSA rule: no named provider still means a lay letter, a technical report, and a referral pathway for probably benign, suspicious, or highly suggestive assessments.
• Mistrust after a prior painful exam, a dismissed lump, or discrimination is a social risk factor for no-show. Culturally competent care here means introducing yourself, explaining compression before you apply it, asking how the patient names her body and gender, and not treating a late-stage presentation as proof the patient “didn’t care.”

Poverty and rural distance produce the same pattern — later stage, harder callbacks — across racial groups. ACS 2026 notes that persistent poverty is associated with higher incidence, later stage, and worse outcomes, compounded by and independent of race. If the exam stem describes a patient who lacks a ride back for diagnostic views, the correct action is to problem-solve the process, not to cancel screening.

Hormone use: HRT, contraception, gender-affirming hormones

Menopausal hormone therapy (HRT). Combined estrogen plus progestin is associated with increased breast cancer risk and can increase mammographic density, which lowers sensitivity — two reasons it belongs on the history. Estrogen-alone therapy after hysterectomy has a different (generally lower) breast-cancer risk profile in the Women’s Health Initiative-era evidence; still document it. “Hormone use” on a form means current and prior, dose if known, and whether the patient stopped recently (density and risk counseling can lag cessation). You do not tell the patient to stop HRT. You record it so the radiologist is not surprised by a dense, nodular pattern and so the referring clinician can discuss risk.

Birth control. Combined oral contraceptives confer a small increase in risk during current use that declines after stopping. Progestin intrauterine devices and other methods have mixed or smaller signals; the exam point is to capture contraceptive hormones, not to rank every product. A young patient on the pill is not “high risk” by that fact alone. Combined with a BRCA mutation or a palpable mass, hormones are still just history — the mass makes the exam diagnostic.

Gender-transition (gender-affirming) hormones. Document sex assigned at birth, current gender, surgeries, and hormone type and duration. That is how you protocol the right anatomy without misgendering the patient.

• Transfeminine patients (estrogen, often with anti-androgens) develop breast tissue. Risk is higher than in cisgender men but is generally treated as closer to average cisgender female risk after sustained exposure. ACR appropriateness materials commonly treat screening mammography as appropriate beginning around age 40 after about 5 years of gender-affirming hormone therapy for average-risk transfeminine patients. Shorter exposure or younger age usually does not follow that same average-risk mammography path. High-risk genetics still dominate. You will still produce an MQSA lay letter with density language if a mammogram is performed.
• Transmasculine patients who have not had chest surgery, or who had reduction rather than oncologic mastectomy, retain breast tissue. ACR-aligned teaching is to follow cisgender female screening unless the referring clinician directs a different plan. Testosterone is not a reason to skip mammography when breasts are present. After gender-affirming chest surgery, residual tissue may be too limited for useful mammography; a palpable concern is often evaluated with ultrasound. Do not invent a “never image after top surgery” rule for a diagnostic lump.

Inclusive intake (“what hormones do you take, including gender-affirming hormones?”) prevents a missed screening in a patient whose legal sex marker no longer matches remaining breast tissue. That is social-risk documentation with a direct imaging implication.